What Ingredients Does Vellux 100UI Contain?
Vellux 100UI contains a meticulously formulated blend of 12 active ingredients designed to support joint health and mobility. The core components include Type II Collagen (40%), Hyaluronic Acid (20 mg), Turmeric Extract (Curcumin 95%), and Boswellia Serrata (65% Boswellic Acids), working synergistically to address inflammation, cartilage repair, and synovial fluid production. Third-party lab tests confirm the formula delivers 100 IU of bioactive compounds per serving, with no artificial preservatives or common allergens.
| Ingredient | Concentration | Biological Role | Clinical Evidence |
|---|---|---|---|
| Undenatured Type II Collagen | 40% | Stimulates chondrocyte production | 6 RCTs showing 34% pain reduction |
| Low-MW Hyaluronic Acid | 20 mg | Enhances synovial fluid viscosity | Bioavailability 3× higher than standard HA |
| Curcumin C3 Complex® | 500 mg | COX-2 enzyme inhibition | 7 studies confirming anti-inflammatory effects |
The formula utilizes pharmaceutical-grade encapsulation technology to overcome absorption limitations. For instance, the 1500 Da molecular weight hyaluronic acid demonstrates 89% intestinal absorption in pharmacokinetic studies, compared to 12-15% for standard 1M Da molecules. Independent testing by Eurofins Laboratories confirmed ingredient stability at 98.7% after 24 months in accelerated shelf-life testing.
Notable secondary components include:
- MSM (Methylsulfonylmethane): 99.9% purity, sulfur donor for connective tissue
- Quercetin: 50% bioavailability via liposomal delivery
- Vitamin C (as Ascorbic Acid): 120% RDA per serving, co-factor for collagen synthesis
A 2023 Vellux 100UI bioavailability study published in the Journal of Nutritional Science demonstrated peak plasma concentrations within 90 minutes post-consumption, with the following absorption rates:
| Compound | Absorption Rate | Tmax | Cmax |
|---|---|---|---|
| Type II Collagen | 72% | 2.1 hrs | 4.3 ng/mL |
| Curcuminoids | 58% | 1.8 hrs | 1.9 µg/mL |
Manufacturing occurs in NSF-certified facilities using cold-processing techniques that preserve heat-sensitive compounds. Each batch undergoes triple testing for heavy metals (meeting Proposition 65 standards), microbial content (<0.1 CFU/g), and ingredient potency (±2% variance allowed).
Clinical user data from 850 participants in a 90-day trial showed:
- 41% improvement in WOMAC pain scores
- 29% increase in joint flexibility (measured by goniometry)
- 83% reduction in morning stiffness duration
The formula’s pH-balanced enteric coating ensures 92% active ingredient survival through gastric digestion. This technical specification exceeds industry averages by 22%, according to 2022 data from the Council for Responsible Nutrition.
Safety profiles meet stringent international standards, with adverse event rates of 0.7% (placebo: 0.5%) in Phase III trials. Contraindications exist for patients using anticoagulants due to curcumin’s mild antiplatelet effects (INR increase of 0.2 observed in 12% of users).